# A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

> **NCT05830097** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Coherent Biopharma (Hefei) Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Cancer, Breast
- Cancer, Lung
- Cancer of Pancreas
- Cancer of Esophagus
- Cancer Colorectal

## Interventions

- **DRUG:** CBP-1019

## Key facts

- **NCT ID:** NCT05830097
- **Lead sponsor:** Coherent Biopharma (Hefei) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-14
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05830097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05830097, "A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05830097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*